Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Subscribe To Our Newsletter & Stay Updated